Gene Editing Technology - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510246109

Publication Date:

October 25, 2024

Pages:

112

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

Gene editing is a new and accurate genetic engineering technology that can modify specific target genes in the genome of an organism.
Gene editing technology refers to the ability for humans to "edit" targeted genes to achieve modifications to specific DNA fragments.
Gene editing relies on genetically engineered nucleases, also known as "molecular scissors," to produce site-specific double-strand breaks (DSBs) at specific locations in the genome, inducing organisms to connect via non-homologous end junctions (NHEJ) or homologous Source Recombination (HR) to repair DSB because this repair process is error-prone, resulting in targeted mutations
The global market for Gene Editing Technology was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Gene Editing Technology was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Gene Editing Technology was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Gene Editing Technology was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Gene Editing Technology include Thermo Fisher Scientific, SIGMA ALDRICH, Dharmacon, Cellectics, CRISPR Therapeutics, AstraZeneca, Bio Rad, Allele Biotech and Recombinetics, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Gene Editing Technology, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gene Editing Technology by region & country, by Type, and by Application.
The Gene Editing Technology market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Editing Technology.
麻豆原创 Segmentation
By Company
Thermo Fisher Scientific
SIGMA ALDRICH
Dharmacon
Cellectics
CRISPR Therapeutics
AstraZeneca
Bio Rad
Allele Biotech
Recombinetics
Lonza
GE Healthcare
Editas Medicine
Agilent Technologies
QIAGEN NV
Segment by Type:
Homologous Recombination
Meganuclease
Segment by Application
Agriculture
Medical
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gene Editing Technology manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Gene Editing Technology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Gene Editing Technology in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Gene Editing Technology Product Introduction
1.2 Global Gene Editing Technology 麻豆原创 Size Forecast
1.3 Gene Editing Technology 麻豆原创 Trends & Drivers
1.3.1 Gene Editing Technology Industry Trends
1.3.2 Gene Editing Technology 麻豆原创 Drivers & Opportunity
1.3.3 Gene Editing Technology 麻豆原创 Challenges
1.3.4 Gene Editing Technology 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Gene Editing Technology Players Revenue Ranking (2023)
2.2 Global Gene Editing Technology Revenue by Company (2019-2024)
2.3 Key Companies Gene Editing Technology Manufacturing Base Distribution and Headquarters
2.4 Key Companies Gene Editing Technology Product Offered
2.5 Key Companies Time to Begin Mass Production of Gene Editing Technology
2.6 Gene Editing Technology 麻豆原创 Competitive Analysis
2.6.1 Gene Editing Technology 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Gene Editing Technology Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Editing Technology as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Homologous Recombination
3.1.2 Meganuclease
3.2 Global Gene Editing Technology Sales Value by Type
3.2.1 Global Gene Editing Technology Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Gene Editing Technology Sales Value, by Type (2019-2030)
3.2.3 Global Gene Editing Technology Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Agriculture
4.1.2 Medical
4.1.3 Other
4.2 Global Gene Editing Technology Sales Value by Application
4.2.1 Global Gene Editing Technology Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Gene Editing Technology Sales Value, by Application (2019-2030)
4.2.3 Global Gene Editing Technology Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Gene Editing Technology Sales Value by Region
5.1.1 Global Gene Editing Technology Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Gene Editing Technology Sales Value by Region (2019-2024)
5.1.3 Global Gene Editing Technology Sales Value by Region (2025-2030)
5.1.4 Global Gene Editing Technology Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Gene Editing Technology Sales Value, 2019-2030
5.2.2 North America Gene Editing Technology Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Gene Editing Technology Sales Value, 2019-2030
5.3.2 Europe Gene Editing Technology Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Gene Editing Technology Sales Value, 2019-2030
5.4.2 Asia Pacific Gene Editing Technology Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Gene Editing Technology Sales Value, 2019-2030
5.5.2 South America Gene Editing Technology Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Gene Editing Technology Sales Value, 2019-2030
5.6.2 Middle East & Africa Gene Editing Technology Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Gene Editing Technology Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Gene Editing Technology Sales Value
6.3 United States
6.3.1 United States Gene Editing Technology Sales Value, 2019-2030
6.3.2 United States Gene Editing Technology Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Gene Editing Technology Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Gene Editing Technology Sales Value, 2019-2030
6.4.2 Europe Gene Editing Technology Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Gene Editing Technology Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Gene Editing Technology Sales Value, 2019-2030
6.5.2 China Gene Editing Technology Sales Value by Type (%), 2023 VS 2030
6.5.3 China Gene Editing Technology Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Gene Editing Technology Sales Value, 2019-2030
6.6.2 Japan Gene Editing Technology Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Gene Editing Technology Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Gene Editing Technology Sales Value, 2019-2030
6.7.2 South Korea Gene Editing Technology Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Gene Editing Technology Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Gene Editing Technology Sales Value, 2019-2030
6.8.2 Southeast Asia Gene Editing Technology Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Gene Editing Technology Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Gene Editing Technology Sales Value, 2019-2030
6.9.2 India Gene Editing Technology Sales Value by Type (%), 2023 VS 2030
6.9.3 India Gene Editing Technology Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Thermo Fisher Scientific
7.1.1 Thermo Fisher Scientific Profile
7.1.2 Thermo Fisher Scientific Main Business
7.1.3 Thermo Fisher Scientific Gene Editing Technology Products, Services and Solutions
7.1.4 Thermo Fisher Scientific Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.1.5 Thermo Fisher Scientific Recent Developments
7.2 SIGMA ALDRICH
7.2.1 SIGMA ALDRICH Profile
7.2.2 SIGMA ALDRICH Main Business
7.2.3 SIGMA ALDRICH Gene Editing Technology Products, Services and Solutions
7.2.4 SIGMA ALDRICH Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.2.5 SIGMA ALDRICH Recent Developments
7.3 Dharmacon
7.3.1 Dharmacon Profile
7.3.2 Dharmacon Main Business
7.3.3 Dharmacon Gene Editing Technology Products, Services and Solutions
7.3.4 Dharmacon Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.3.5 Cellectics Recent Developments
7.4 Cellectics
7.4.1 Cellectics Profile
7.4.2 Cellectics Main Business
7.4.3 Cellectics Gene Editing Technology Products, Services and Solutions
7.4.4 Cellectics Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.4.5 Cellectics Recent Developments
7.5 CRISPR Therapeutics
7.5.1 CRISPR Therapeutics Profile
7.5.2 CRISPR Therapeutics Main Business
7.5.3 CRISPR Therapeutics Gene Editing Technology Products, Services and Solutions
7.5.4 CRISPR Therapeutics Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.5.5 CRISPR Therapeutics Recent Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Profile
7.6.2 AstraZeneca Main Business
7.6.3 AstraZeneca Gene Editing Technology Products, Services and Solutions
7.6.4 AstraZeneca Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.6.5 AstraZeneca Recent Developments
7.7 Bio Rad
7.7.1 Bio Rad Profile
7.7.2 Bio Rad Main Business
7.7.3 Bio Rad Gene Editing Technology Products, Services and Solutions
7.7.4 Bio Rad Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.7.5 Bio Rad Recent Developments
7.8 Allele Biotech
7.8.1 Allele Biotech Profile
7.8.2 Allele Biotech Main Business
7.8.3 Allele Biotech Gene Editing Technology Products, Services and Solutions
7.8.4 Allele Biotech Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.8.5 Allele Biotech Recent Developments
7.9 Recombinetics
7.9.1 Recombinetics Profile
7.9.2 Recombinetics Main Business
7.9.3 Recombinetics Gene Editing Technology Products, Services and Solutions
7.9.4 Recombinetics Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.9.5 Recombinetics Recent Developments
7.10 Lonza
7.10.1 Lonza Profile
7.10.2 Lonza Main Business
7.10.3 Lonza Gene Editing Technology Products, Services and Solutions
7.10.4 Lonza Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.10.5 Lonza Recent Developments
7.11 GE Healthcare
7.11.1 GE Healthcare Profile
7.11.2 GE Healthcare Main Business
7.11.3 GE Healthcare Gene Editing Technology Products, Services and Solutions
7.11.4 GE Healthcare Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.11.5 GE Healthcare Recent Developments
7.12 Editas Medicine
7.12.1 Editas Medicine Profile
7.12.2 Editas Medicine Main Business
7.12.3 Editas Medicine Gene Editing Technology Products, Services and Solutions
7.12.4 Editas Medicine Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.12.5 Editas Medicine Recent Developments
7.13 Agilent Technologies
7.13.1 Agilent Technologies Profile
7.13.2 Agilent Technologies Main Business
7.13.3 Agilent Technologies Gene Editing Technology Products, Services and Solutions
7.13.4 Agilent Technologies Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.13.5 Agilent Technologies Recent Developments
7.14 QIAGEN NV
7.14.1 QIAGEN NV Profile
7.14.2 QIAGEN NV Main Business
7.14.3 QIAGEN NV Gene Editing Technology Products, Services and Solutions
7.14.4 QIAGEN NV Gene Editing Technology Revenue (US$ Million) & (2019-2024)
7.14.5 QIAGEN NV Recent Developments
8 Industry Chain Analysis
8.1 Gene Editing Technology Industrial Chain
8.2 Gene Editing Technology Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Gene Editing Technology Sales Model
8.5.2 Sales Channel
8.5.3 Gene Editing Technology Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Thermo Fisher Scientific
SIGMA ALDRICH
Dharmacon
Cellectics
CRISPR Therapeutics
AstraZeneca
Bio Rad
Allele Biotech
Recombinetics
Lonza
GE Healthcare
Editas Medicine
Agilent Technologies
QIAGEN NV

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.